Souvenaid for Alzheimer's disease

Area of Science:

• Neurology
• Nutritional Neuroscience
• Gerontology

Background:

• Souvenaid is a specialized dietary supplement containing Fortasyn Connect™ designed for individuals with Alzheimer's disease (AD).
• It aims to support synaptic formation and function, crucial for cognitive processes potentially impacted by AD.
• The supplement's efficacy in managing AD symptoms and preventing progression from mild cognitive impairment (MCI) to dementia is under investigation.

Purpose of the Study:

• To evaluate the impact of Souvenaid on the incidence of dementia in individuals with AD.
• To assess Souvenaid's effects on cognitive function and functional performance in AD patients.
• To determine the safety and tolerability profile of Souvenaid in the AD population.

Main Methods:

• A systematic review of randomized, placebo-controlled trials (RCTs) was conducted.
• Searches included major databases (MEDLINE, Embase, PsycINFO, etc.) and clinical trial registries up to June 2020.
• Included trials evaluated Souvenaid in individuals with prodromal AD or mild-to-moderate AD dementia, with a minimum treatment duration of 16 weeks.

Main Results:

• Three RCTs involving 1097 participants were included, with low risk of bias.
• Souvenaid did not significantly reduce the incidence of dementia in prodromal AD after 24 months (moderate quality evidence).
• Cognitive functions and daily living activities showed little to no difference between Souvenaid and placebo groups across different AD stages (moderate quality evidence).

Conclusions:

• Souvenaid treatment likely does not prevent progression to dementia in prodromal AD and shows minimal impact on cognitive or functional outcomes in mild-to-moderate AD.
• Conflicting results on combined cognitive-functional outcomes warrant further investigation, particularly in prodromal AD.
• While adverse effects appear uncommon, definitive conclusions on long-term tolerability and efficacy in severe AD or at-risk populations remain unclear.